title: Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study.
abstract: BACKGROUND
  Highly purified hMG (hp-hMG) has recently shown better cycle outcome than the recombinant FSH (rFSH) when compared in GnRH agonist long protocol cycles. However, they have not yet been compared in GnRH antagonist cycles.
  
  
  METHODS
  A RCT comparing the ongoing pregnancy rate (primary end-point) in 280 patients undergoing IVF/ICSI after stimulation with hp-hMG or rFSH controlled with a GnRH antagonist.
  
  
  RESULTS
  No significant differences were observed between hp-hMG and rFSH in terms of the ongoing pregnancy rate per started cycle (35.0 versus 32.1%, respectively; P = 0.61); relative risk: 1.09 (95% confidence interval: 0.78-1.51; risk difference: 2.9%). No differences were observed for implantation, clinical pregnancy and pregnancy loss rates. More oocytes were obtained from patients receiving rFSH then hMG (14.4 +/- 8.1 versus 11.3 +/- 6.0, respectively; P = 0.001). Estradiol was higher at the end of stimulation in the hp-hMG group (P = 0.02), whereas progesterone was higher in patients stimulated with rFSH (P < 0.001).
  
  
  CONCLUSIONS
  A similar outcome was observed for hp-hMG and rFSH when used for stimulation in GnRH antagonist cycles. However, some differences were found in ovarian response in terms of oocyte yield and hormonal profile. Clinical Trials.gov
  
  
  BACKGROUND
  NCT00669786.
authors.affiliation: Instituto Valenciano de Infertilidad, E-46015 Valencia, Valencia 46015, Spain. ebosch@ivi.es
authors.forename: E
authors.initials: E
authors.lastname: Bosch
authors.forename: C
authors.initials: C
authors.lastname: Vidal
authors.forename: E
authors.initials: E
authors.lastname: Labarta
authors.forename: C
authors.initials: C
authors.lastname: Simon
authors.forename: J
authors.initials: J
authors.lastname: Remohi
authors.forename: A
authors.initials: A
authors.lastname: Pellicer
mesh_terms: D000293:Adolescent; D000328:Adult; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D008596:Menotropins / Q000627:therapeutic use*; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D008596:Menotropins; D005640:Follicle Stimulating Hormone